Results from a Phase-II Clinical Trial of Baricitinib

Baricitinib works by interfering with signaling pathways inside immune cells, to reduce inflammation and lower the immune system. It is part of a class of drugs called Janus kinase (JAK) inhibitors. JAK comes in two forms, JAK1 and JAK2, and Baricitinib targets both of them. Baricitinib is not a new drug; it was first approved by the US Food and Drug Administration (FDA) in 2018. It is taken as a…